Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.
Show more...
CEO
Dr. Jan Skvarka
직원
33
국가
CA
상장
0 Comments
생각을 공유하기
FAQ
오늘 Trillium Therapeutics 주가는 얼마인가요?▼
TRIL.TO의 현재 가격은 C$23.33 CAD이며, 지난 24시간 동안 +0.47% 상승했습니다. 차트에서 Trillium Therapeutics 주가 흐름을 더 자세히 살펴보세요.
Trillium Therapeutics의 주식 심볼은 무엇인가요?▼
거래소에 따라 주식 심볼이 다를 수 있습니다. 예를 들어, 거래소에서는 Trillium Therapeutics 주식이 TRIL.TO 심볼로 거래됩니다.